Drugmaker Merck & Co Inc
said on Monday that the combination of its cancer
immunotherapy Keytruda with Pfizer Inc’s Inlyta cut the
risk of death nearly in half for patients with the most common
form of kidney cancer when compared with treatment with
chemotherapy drug Sutent.
JEFFREY LIPTON in BARBADOS – http://feeds.reuters.com/~r/reuters/companyNews/~3/K4omwek1PZM/refile-merck-pfizer-combo-treatment-boosts-kidney-cancer-survival-idUSL1N20700Q